Health

Results: 121-132 of 10101

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 2026

PR Newswire associated0

Opella: New study demonstrates successful cough treatment extends beyond symptom relief

A new study led by Will Rutland of UAB Montgomery and funded by Baszucki Group aims to improve access to psychiatric treatment in rural areas. By partnering with a local food bank, researchers will evaluate both the psychiatric and metabolic effects of ketogenic therapy alongside existing treatment modalities for people with bipolar disorder in Central Alabama.

New Study Brings Ketogenic Therapy for Bipolar Disorder Directly to Rural Alabama Homes

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

PR Newswire associated0

Hers Launches Clinician-Led Hair Loss Care for Women Across the UK

PR Newswire associated0

Cumulus Neuroscience and Transpharmation Partner to Carry Objective EEG Measurement from Preclinical Research into First-in-Human Studies

PR Newswire associated0

Kedrion: at ESID 2026, experts call for earlier diagnosis and greater awareness as Secondary Immunodeficiencies continue to rise

SciBase secures first payer coverage with Highmark, marking a major commercial inflection point